Medical News Today: ALS: A new therapy may be in sight
New research, led by Harvard scientists, identifies a novel potential therapeutic target for treating amyotrophic lateral sclerosis (ALS). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 17, 2019 Category: Consumer Health News Tags: Muscular Dystrophy / ALS Source Type: news

#MayoClinicRadio podcast: 1/12/19
Listen: Mayo Clinic Radio 1/12/19 On the Mayo Clinic Radio podcast,?Dr. Jennifer Martinez-Thompson, a Mayo Clinic neurologist, discusses diagnosis and treatment options for amyotrophic lateral sclerosis (ALS). Also on the podcast, Dr. Molly Jeffery?and Dr. W. Michael Hooten?share new Mayo Clinic research on trends in opioid use.?Dr. Jeffery is the scientific director of Emergency Medicine [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 14, 2019 Category: Databases & Libraries Source Type: news

National Geographic Takes an Interest in Organs-on-Chips Research
Biomedical researchers at Cedars-Sinai Medical Center in Los Angeles, CA have caught the attention of National Geographic. The magazine published a special edition this month covering "The Future of Medicine" that highlights the innovative stem-cell science of Cedars-Sinai, showing how investigators there are seeking to use stem cells and organs-on-chips to tailor personalized medical treatments. The cover photo of the special issue features research being conducted at Cedars-Sinai in collaboration with Boston, MA-based Emulate, a startup developing a tissue-based technology designed to replicate human organ-leve...
Source: MDDI - January 11, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Source Type: news

New Technique Could Be a Breakthrough for Motility Research
In this study, we showed a mitigation of these common problems with optogenetic muscle control,” said Hugh Herr, who led the research team and heads the Media Lab’s Biomechatronics group. “This has great promise for the development of solutions for patients suffering from debilitating conditions like muscle paralysis.” The group's research paper was published in the Dec. 13 issue of Nature Communications. Doctors already use electrical nerve stimulation to treat patients with spinal cord injury, and to improve muscle conditionin...
Source: MDDI - January 2, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Source Type: news

10 Top Questions You Had For Dr. Google In 2018
(CNN) — People were curious about the keto diet, ALS and endometriosis in 2018. Those are just a few of the health-related topics that had Internet surfers in the United States turning to Dr. Google with questions this year, according to a top 10 list from the search engine giant. The data, based on search terms, was collected from January to mid-December. Last year, some of the top health-related questions searched on Google included what causes hiccups, how to stop snoring, how long flu lasts and what is lupus. Some of the top health-related questions on Google in 2016 were related to Zika, traumatic brain injuries...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 21, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Offbeat Google Local TV Source Type: news

Prevalence of Amyotrophic Lateral Sclerosis -- US, 2015 Prevalence of Amyotrophic Lateral Sclerosis -- US, 2015
The prevalence data presented in this report aims to further our understanding of the epidemiology of ALS cases in the United States.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Regulated proteolysis of p62/SQSTM1 enables differential control of autophagy and nutrient sensing
The multidomain scaffold protein p62 (also called sequestosome-1) is involved in autophagy, antimicrobial immunity, and oncogenesis. Mutations in SQSTM1, which encodes p62, are linked to hereditary inflammatory conditions such as Paget’s disease of the bone, frontotemporal dementia (FTD), amyotrophic lateral sclerosis, and distal myopathy with rimmed vacuoles. Here, we report that p62 was proteolytically trimmed by the protease caspase-8 into a stable protein, which we called p62TRM. We found that p62TRM, but not full-length p62, was involved in nutrient sensing and homeostasis through the mechanistic target of rapam...
Source: Signal Transduction Knowledge Environment - December 4, 2018 Category: Science Authors: Sanchez-Garrido, J., Sancho-Shimizu, V., Shenoy, A. R. Tags: STKE Research Articles Source Type: news

Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
If approved, BHV-0223 would become the only formulation of riluzole that does not require swallowing tablets or liquids, offering an important delivery alternative for the standard-of-care treatment of ALS Riluzole is the only FDA-approved treatment for... Biopharmaceuticals, Neurology, Drug Delivery, FDA Biohaven Pharmaceutical, riluzole, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 26, 2018 Category: Pharmaceuticals Source Type: news

CDC: U.S. Prevalence of ALS Was 5.2 Per 100,000 in 2015
MONDAY, Nov. 26, 2018 -- In 2015, the prevalence of amyotrophic lateral sclerosis (ALS) in the United States was 5.2 per 100,000 population, with 16,583 cases identified, according to research published in the Nov. 23 issue of the U.S. Centers for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 26, 2018 Category: Pharmaceuticals Source Type: news

Wish to die and reasons for living among patients with amyotrophic lateral sclerosis - Verschueren A, Kianimehr G, Belingher C, Salort-Campana E, Loundou A, Grapperon AM, Attarian S.
OBJECTIVE: In Amyotrophic lateral sclerosis (ALS), disease severity, ineffective treatment, and increasing dependence on caregivers may give rise to hopelessness and suicidal ideation among patients. In clinical practice, the desire for death among patient... (Source: SafetyLit)
Source: SafetyLit - November 17, 2018 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

New way to study swallowing could one day lead to improved treatments for ALS
(University of Missouri-Columbia) There is no cure for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, but new findings from the University of Missouri School of Medicine and the University of Missouri College of Veterinary Medicine are deepening researchers' understanding of a common ALS symptom: swallowing problems. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2018 Category: International Medicine & Public Health Source Type: news

Trying to understand cells' interior design
(Institute for Basic Science) IBS Scientists have explained how liquid-like droplets made of proteins and DNA form in vitro. Currently, there is a huge interest in understanding the molecular mechanisms behind the creation of such droplets, as it is linked to some human diseases, such as amyotrophic lateral sclerosis (ALS). The results showed how much the sequence of DNA matters in the formation of such droplets. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 6, 2018 Category: Biology Source Type: news

Researchers identify promising proteins for diagnostic, prognostic use in ALS
(North Carolina State University) Researchers from North Carolina State University have identified proteins that may be useful in both earlier diagnosis of Amyotrophic Lateral Sclerosis (ALS) and in more accurate disease prognosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 5, 2018 Category: International Medicine & Public Health Source Type: news

Normal function of ALS and dementia linked gene determined for the first time
(University of Bath) The normal function of a gene associated with the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has been determined for the first time by University of Bath scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2018 Category: International Medicine & Public Health Source Type: news

CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders
Agreement with University California San Diego Provides License for Production of SynCav1, an Investigational Novel Gene Therapy for Treatment of Alzheimer's Disease and Amyotrophic Lateral Sclerosis GLEN BURNIE, Md., Oct. 23, 2018 -- (Healthcare Sales ... Biopharmaceuticals, Neurology, Licensing CavoGene LifeSciences, SynCav1, Alzheimer's disease, neurodegenerative disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 23, 2018 Category: Pharmaceuticals Source Type: news

Organs-on-chip technology reveals new drug candidates for Lou Gehrig's disease
The investigation of amyotrophic lateral sclerosis (ALS) - also known as Lou Gehrig's disease - through muscle-on-a-chip technology has revealed a new drug combination that may serve as an effective treatment of the progressive neurodegenerative disease. These findings highlight organ-on-a-chip technologies - in which live conditions of the body are mimicked in a microfluidic cell culture - as promising platforms for (Source: World Pharma News)
Source: World Pharma News - October 10, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members - Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR.
OBJECTIVE: The aim of this study was to determine in a systematic manner if the C9orf72 phenotype might extend beyond frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) to include psychiatric disease. METHODS: A validated ... (Source: SafetyLit)
Source: SafetyLit - October 5, 2018 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Cognitive and Behavior Changes Common Early in ALS Cognitive and Behavior Changes Common Early in ALS
New evidence shows that unlike previously thought, behavior and cognitive domains are significantly affected early in the course of amyotrophic lateral sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

ALS Affects the Mind, Not Just the Body
THURSDAY, Sept. 13, 2018 -- The minds of patients suffering from amyotrophic lateral sclerosis (ALS) are damaged by the disease, despite the longstanding belief that this was not the case, a new study reveals. In fact, in the later stages of ALS,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news

Finding that links ALS/ataxia to cellular stress opens new approaches for treatment
(University of Utah) Scientists at University of Utah Health report for the first time that a protein, called Staufen1, accumulates in cells of patients suffering from degenerative ataxia or amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Depleting the protein from affected mice improved symptoms including motor function. These results suggest that targeting Staufen1 could have therapeutic potential in people. The research is published in Nature Communications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 7, 2018 Category: International Medicine & Public Health Source Type: news

ITF Pharma Announces FDA Approval of Tiglutik (riluzole) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
BERWYN, Pa., Sept. 6, 2018 /PRNewswire/ -- ITF Pharma, a U.S.-based specialty pharmaceutical company and a subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, committed to investing in and commercializing impactful... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 6, 2018 Category: Drugs & Pharmacology Source Type: news

Berwyn pharma firm gets approval for ALS drug
The Food and Drug Administration has approved ITF Pharma ’s new drug application for Tiglutik, a treatment for amyotrophic lateral sclerosis or ALS. Tiglutik is, according to ITF Pharma, the first and only easy-to-swallow thickened riluzole liquid for ALS. The medicine is administered twice daily by oral syringe. ALS, also known as Lou Gehrig’s dise ase, is a progressive and ultimately fatal neurodegenerative disease marked by a gradual degeneration of nerve cells of the central nervous system… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 6, 2018 Category: Biotechnology Authors: John George Source Type: news

Patient Distressed by Overturn of California End of Life Option Act
TUESDAY, Sept. 4, 2018 -- The decision to overturn the End of Life Option Act has added stress and anxiety to terminally ill patients, including those with amyotrophic lateral sclerosis (ALS), according to a patient testimonial published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2018 Category: Pharmaceuticals Source Type: news

Infographic: Exploring New Therapeutic Targets in ALS
Biological insights from the last decade of research on amyotrophic lateral sclerosis are revealing novel opportunities for treatment. (Source: The Scientist)
Source: The Scientist - September 1, 2018 Category: Science Tags: Infographics Source Type: news

The molecular link between aging and neurodegeneration
(Harvard Medical School) Harvard Medical School researchers have discovered a molecular link between aging and a major genetic cause of both amyotrophic lateral sclerosis and frontotemporal dementia, two related neurodegenerative diseases with shared genetic risk factors. The findings reveal possible new targets for treatment of these and other neurodegenerative diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 23, 2018 Category: International Medicine & Public Health Source Type: news

Quantification of motor neuron loss and muscular atrophy in ricin-induced focal nerve injury - Liang Y, Zhang J, Walczak P, Bulte JWM.
The objective of this study was... (Source: SafetyLit)
Source: SafetyLit - August 2, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Molecular culprits of protein aggregation in ALS and FTLD
(VIB (the Flanders Institute for Biotechnology)) The mutated and aggregated protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers led by prof. Ludo Van Den Bosch (VIB-KU Leuven) have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2018 Category: International Medicine & Public Health Source Type: news

New therapy extends ALS survival, reverses neuromuscular damage in animals
A therapy for an inherited form of amyotrophic lateral sclerosis extends survival and reverses signs of neuromuscular damage in mice and rats, a new study shows. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 17, 2018 Category: Consumer Health News Source Type: news

Some existing anti-cancer drugs may act in part by targeting RNA
Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells. The research offers another approach for tackling diseases that have been considered "undruggable," including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers. (Source: World Pharma News)
Source: World Pharma News - June 29, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Some existing anti-cancer drugs may act in part by targeting RNA, study shows
(Scripps Research Institute) The research offers another approach for tackling diseases that have been considered 'undruggable,' including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2018 Category: International Medicine & Public Health Source Type: news

Rasagiline Added to Riluzole in ALS May Help'Fast Progressors'Rasagiline Added to Riluzole in ALS May Help'Fast Progressors '
Adding rasagiline to riluzole did not extend survival, the primary endpoint, in amyotrophic lateral sclerosis, but post hoc analysis suggests it may benefit those deemed'fast progressors. 'Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New funding to UC Riverside to significantly boost cancer, ALS research
(University of California - Riverside) Maurizio Pellecchia at the University of California, Riverside has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. The first grant from the US-Egypt Science and Technology Joint Fund of the National Academy of Sciences, Engineering, and Medicine totals $190,000 for two years. The second is a nearly $2.3 million, five-year grant from the National Institute of Neurological Disorders and Stroke. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 21, 2018 Category: Cancer & Oncology Source Type: news

Aquinnah Pharmaceuticals receives $3.4 million grant from NINDS to advance new therapies for ALS
(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 20, 2018 Category: Biology Source Type: news

AcuraStem receives fast-track SBIR grant
(AcuraStem, Inc.) AcuraStem, a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, 'AS2015', focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2018 Category: International Medicine & Public Health Source Type: news

Boston ’s Flex Pharma slashes headcount, eyes sale after ALS drug fails
Boston-based Flex Pharma will lay off most of its employees and explore a potential sale or merger after ending a mid-stage trial of its lead drug, which targets several diseases including amyotrophic lateral sclerosis, or ALS. Flex (Nasdaq: FLKS) announced Wednesday that it had halted a Phase 2 study of the drug, called FLX-787, in patients with either ALS or neurological disorder Charcot-Marie-Tooth disease. The company cited “oral tolerability concerns,” though it said that the drug had helped… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 13, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Immunotherapy Promising for Slowing Progression of ALS
MONDAY, June 4, 2018 -- A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis (ALS), according to a phase 1, first-in-human study published online May 18 in Neurology: Neuroimmunology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

Goodbye 'stress granules': Study expands possibilities for treating neurological diseases
(Tokyo Institute of Technology) Cell biologists have deepened understanding of proteins associated with neurodegenerative diseases. The findings could open up new treatment approaches for disorders including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), among others. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 30, 2018 Category: International Medicine & Public Health Source Type: news

ALS Progression Faster in Hypermetabolic Patients ALS Progression Faster in Hypermetabolic Patients
Patients with amyotrophic lateral sclerosis (ALS) who are hypermetabolic show greater functional decline and shorter survival, according to Australian researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

What helps form long-term memory also drives the development of neurodegenerative disease
(Trinity College Dublin) Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in Amyotrophic Lateral Sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 22, 2018 Category: International Medicine & Public Health Source Type: news

Post-doctoral position at Laboratory of Central and Peripheral Mechanisms of Neurodegeneration, Strasbourg University
A post-doctoral position is available at the Inserm Laboratory of Central and Peripheral Mechanisms of Neurodegeneration (UMR-S1118) team, to study the role of the hypothalamus in amyotrophic lateral sclerosis.The team has previously identified structural and functional deficits in the hypothalamus of ALS mouse models and patients (Vercruysse et al, Brain, 2016; Gorges, Vercruysse et al., JNNP, 2017; for review see Vercruysse et al, Frontiers, 2018) and identified alterations in selected neuronal types in the hypothalamus of mouse models. They now aim at using mouse genetics, combined with pharmacogenetics,&nb...
Source: Society for Endocrinology - May 16, 2018 Category: Endocrinology Source Type: news

FDA Lays the Smackdown on Illegal Stem Cell Clinics
FDA is cracking down on stem cell clinics that market unapproved products and don't meet good manufacturing practice requirements. On behalf of the agency, the Department of Justice filed two complaints in federal court this week seeking permanent injunctions against a Florida-based clinic and a California-based clinic.  “Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk. In some instances, patients have suffered serious and per...
Source: MDDI - May 10, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Companies to use data in battle against Parkinson's, Alzheimer's, ALS
Morrisville-based contract research organization Worldwide Clinical Trials and Roivant-backed health care technology company Datavant are partnering to take on neurodegenerative diseases. Some of the most common neurodegenerative diseases include Parkinson's, Alzheimer's, Huntington's and amyotrophic lateral sclerosis, or ALS. According to Worldwide and Datavant, the most common neurodegenerative diseases cost the U.S. close to $800 billion annually.  Through the new partnership, Worldwide and… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 8, 2018 Category: American Health Authors: Jennifer Henderson Source Type: news

Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
SAN BRUNO, Calif. and LOS ANGELES, April 26, 2018 -- (Healthcare Sales & Marketing Network) -- Neuraltus Pharmaceuticals, Inc., a privately-held pharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, today a... Biopharmaceuticals, Neurology Neuraltus Pharmaceuticals, Amyotrophic Lateral Sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 26, 2018 Category: Pharmaceuticals Source Type: news

Linear Link for Physical Activity, Amyotrophic Lateral Sclerosis
TUESDAY, April 24, 2018 -- There is a linear correlation for physical activity (PA) with amyotrophic lateral sclerosis (ALS), according to a study published online April 23 in the Journal of Neurology, Neurosurgery& Psychiatry. Anne E. Visser,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2018 Category: Pharmaceuticals Source Type: news

Extreme Exercisers May Have Higher Odds for ALS
MONDAY, April 23, 2018 -- Fitness buffs who push themselves to the limit during workouts might slightly increase their risk of developing amyotrophic lateral sclerosis (ALS), a new study suggests. The same may hold true for working stiffs whose jobs... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 23, 2018 Category: General Medicine Source Type: news

Two genes associated with ALS risk identified
Two previously unrecognized genetic risks that are significantly associated with amyotrophic lateral sclerosis have been identified by researchers. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 10, 2018 Category: Consumer Health News Source Type: news

UCSF researcher identifies risk genes for ALS
(University of California - San Francisco) The largest analysis to date of genetic data in amyotrophic lateral sclerosis (ALS) -- the muscle-crippling neurodegenerative disease that afflicted the late astrophysicist Stephen Hawking and cut short the career of iconic Yankee baseball slugger Lou Gehrig -- has identified two previously unrecognized genetic risks that are significantly associated with the disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 9, 2018 Category: Infectious Diseases Source Type: news

ALS, rare dementia share genetic link
(Washington University School of Medicine) Studying data from more than 125,000 individuals, an international team of researchers led by scientists at Washington University School of Medicine in St. Louis has identified genetic links between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The link between the seemingly unrelated disorders suggests that some drugs developed to treat ALS also may work against frontotemporal dementia and vice versa. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 9, 2018 Category: International Medicine & Public Health Source Type: news

Brain's tiniest blood vessels trigger spinal motor neurons to develop
(Cedars-Sinai Medical Center) A new study has revealed that the human brain's tiniest blood vessels can activate genes known to trigger spinal motor neurons, prompting the neurons to grow during early development. The findings could provide insights into how amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders may develop. To make the discovery, investigators successfully re-created living tissues of the blood vessels and the spinal motor neurons -- which control muscles -- outside the body to show how they interact. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 23, 2018 Category: International Medicine & Public Health Source Type: news

BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 21, 2018 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the ... Regenerative Medicine, Neurology, Personnel BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2018 Category: Pharmaceuticals Source Type: news